CDC Leadership Shakeup Raises Concerns for Hospitals

Acting director appointment and staff departures spark uncertainty around outbreak coordination, public health guidance, and disease surveillance.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

The Centers for Disease Control and Prevention (CDC) is facing a leadership crisis with three director changes since July and significant staff departures, raising concerns about the agency's ability to deliver the outbreak coordination, surveillance, and public health guidance that hospitals have relied on for decades. The recent appointment of NIH director Jay Bhattacharya as acting CDC director, along with the resignation of the CDC's Principal Deputy Director, has sparked questions about the feasibility of one individual leading both agencies concurrently.

Why it matters

The CDC's role as the main coordinating body for infectious disease outbreaks and public health emergencies is critical for hospitals, which depend on the agency's guidance and support during health crises. The leadership and workforce churn raises uncertainty about the level of federal assistance hospitals can expect during the next outbreak, as well as concerns about the timeliness and currency of the CDC's clinical guidance on issues like infection control, antimicrobial stewardship, and vaccine recommendations.

The details

After the ouster of former CDC director Susan Monarez, PhD, in August, the agency has seen a series of leadership changes, with HHS Deputy Secretary Jim O'Neill serving as acting director before being replaced by NIH director Jay Bhattacharya, MD, on February 18. Just five days later, the CDC's Principal Deputy Director Ralph Abraham, MD, resigned due to 'unforeseen family obligations'. Public health experts have voiced concerns about Dr. Bhattacharya's ability to concurrently run the NIH and CDC, given his lack of formal public health training and the geographical distance between the two agencies. The CDC has also undergone significant workforce changes through firings and resignations, including the departure of many career leaders.

  • In July, former CDC director Susan Monarez, PhD, was ousted from her role.
  • In August, HHS Deputy Secretary Jim O'Neill was appointed as acting CDC director.
  • On February 18, 2026, NIH director Jay Bhattacharya, MD, was named as the new acting CDC director.
  • On February 23, 2026, the CDC's Principal Deputy Director Ralph Abraham, MD, resigned due to 'unforeseen family obligations'.

The players

Jay Bhattacharya

A physician and medical economist who researches the well-being of populations, and the current acting director of the CDC. He also serves as the director of the National Institutes of Health.

Susan Monarez

The former CDC director who was ousted from her role in July.

Jim O'Neill

The HHS Deputy Secretary who served as acting CDC director after Susan Monarez's departure.

Ralph Abraham

The former Principal Deputy Director of the CDC, who resigned on February 23, 2026 due to 'unforeseen family obligations'.

Debra Houry

The former chief medical officer and deputy director for program and science at the CDC.

Got photos? Submit your photos here. ›

What they’re saying

“One disaster away from being a disaster itself.”

— Michael Osterholm, Director of the Center for Infectious Disease Research and Policy at the University of Minnesota (The New York Times)

What’s next

President Donald Trump has not yet named a permanent nominee for the top CDC role, and it could take several months for Senate confirmation once a nominee is identified, leaving the CDC without a full-time executive leader for an indefinite period.

The takeaway

The leadership and workforce churn at the CDC raises serious concerns about the agency's ability to fulfill its core functions that hospitals rely on, including outbreak coordination, public health guidance, and disease surveillance. Healthcare leaders face growing uncertainty about the level of federal support they can expect during the next health crisis, as well as the timeliness and currency of the CDC's clinical recommendations.